



# Response to the Procedural Review Panel's Memorandum Report on the Procedural Review of Tafasitamab (Minjuvi)

## Background

The Procedures for CADTH Reimbursement Reviews (the Procedures) define the steps CADTH will take in the development of a final recommendation issued by a CADTH expert committee for a pharmaceutical reimbursement review (reimbursement review).

A procedural review provides our stakeholders with an opportunity to engage with us if they perceive CADTH failed to act in accordance with the Procedures in conducting a reimbursement review and issuing a final recommendation. This mechanism is an important part of maintaining fair and accountable reimbursement reviews.

## Request for a Procedural Review

A procedural review request for tafasitamab was received and accepted by CADTH in November 2022. A Procedural Review Panel (the Panel) was convened to adjudicate the procedural review regarding the final recommendation issued by the CADTH pCODR Expert Review Committee (pERC).

The Panel's mandate relates only to determining whether CADTH deviated from the Procedures in conducting a reimbursement review and issuing a final recommendation made by an expert committee.

## Panel Decision

The Panel concluded that the reimbursement review of tafasitamab did not deviate from the established Procedures. The Panel provided its findings and decision in a [memorandum report](#) to CADTH.

The Procedures state that the objectives of CADTH's reimbursement review processes are to "reduce duplication across jurisdictions, maximize the use of limited resources, and enhance the consistency of drug reviews." As identified in previous decisions, the Panel found that the reference to "consistency of drug reviews" does not mean consistency with the level of evidence provided for previous drug reviews, and that this does not represent an argument for a breach of the Procedures. The Panel recommended that a clearer statement about this theme be reflected in the Procedures to remove this issue from further debate.

## CADTH Response

CADTH extends its thanks to the members of the Panel for adjudicating this procedural review. The Panel's contributions are an integral component of this important process, and we greatly appreciate their time and effort in appraising the issues raised.

CADTH ensures that all submissions to the CADTH Reimbursement Review program are treated fairly through the consistent application of the steps established in the Procedures. The scientific review of each drug is independent of any product that preceded it because new developments in the treatment landscape and in clinical practice may change unmet needs over time. The same deliberative or decision-making process is applied to each submission to enhance the consistency of reviews across provincial and territorial jurisdictions. This is complemented by a robust conflict of interest policy that ensures the integrity of the recommendations.

## Next Steps

CADTH is committed to reviewing its processes and the Procedures to identify where there are opportunities for improvement. Revisions to the Procedures are underway and will incorporate a clearer statement about what CADTH means by *consistency* in its reviews. It is expected that an updated version of the Procedures will be posted by the end of February 2023.

## Questions

Questions about this procedural review should be directed to Jocelyn Chisamore, Director, Strategy and Governance, via [requests@cadth.ca](mailto:requests@cadth.ca).